The findings also reveal that, although a variety of suitable treatments for the indication are available, new therapies are required that will meet the needs of subsets of colorectal cancer patients. Several treatments that are expected to launch by 2019 will meet some of the needs of heavily pretreated patients with KRAS (Kirsten rat sarcoma viral oncogene homologue) mutations, patients with liver metastases and high-risk stage II patients. These late-stage therapies include AEterna Zentaris/Keryx Biopharmaceuticals' perifosine (KRX-0401), Light Sciences Oncology/Nippon Petrochemicals/Meiji Seika Kaisha's Aptocine/Laserphyrin (talaporfin) and the OncoVax vaccine, Vaccinogen.
"However, we forecast that none of these late-stage therapies will achieve blockbuster sales for colorectal cancer," Ms. Jammen said.
About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.
About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision
|SOURCE Decision Resources|
Copyright©2010 PR Newswire.
All rights reserved